乐
乐观
乐观 · 25%IMMX
$3.24
情景价格
$8.680
+0.174 (+2.00%)收盘时
Loading chart…
- 最高
- 8.905
- 开盘
- 8.510
- 成交量加权均价
- 8.68
- 成交量
- 1.31M
- 市值
- 56.26M
- 最低
- 8.450
- 成交额
- 11.41M
- 企业价值/息税折旧摊销前利润（TTM）
- 0.00
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
AI 分析 of Immix Biopharma Inc (IMMX)
买入Immix Biopharma Inc is a good buy right now due to its promising clinical trial results for NXC-201, which showed an 89% complete response rate, and a significant price target increase from analysts, with BofA setting it at $30, indicating over 190% upside potential from the current price of $9.46. However, the stock has experienced a 22.08% decline over the last 20 days, which presents a risk to consider.
估值指标
Immix Biopharma Inc（IMMX）当前预期市盈率为 0.00，5 年平均预期市盈率为 -3.84。
Alphio AI 对 IMMX 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
持有 IMMX 的大户
事件时间线
资讯
6.009-29stocktwitsBofA Raises Immix Price Target to $30 Amid Positive NXC-201 Data
2.009-29NASDAQ.COMImmix Biopharma Reports Promising NXC-201 Phase 2 Results
9.009-29NASDAQ.COMImmix Biopharma Reports Significant Interim Results for NXC-201 in AL Amyloidosis
7.008-13PRnewswirePomerantz LLP Investigates Securities Fraud Claims Against Immix Biopharma
7.008-07PRnewswirePomerantz LLP Investigates Securities Fraud Claims Against Immix Biopharma
IMMX 常见问题 —— 由 Alphio AI 解答
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Immix Biopharma Inc is a good buy right now due to its promising clinical trial results for NXC-201, which showed an 89% complete response rate, and a significant price target increase from analysts, with BofA setting it at $30, indicating over 190% upside potential from the current price of $9.46. However, the stock has experienced a 22.08% decline over the last 20 days, which presents a risk to consider.
社区
更多 ↗
$IMMX Immix Biopharma prices 11.36M share registered offering at $11.00 Immix Biopharma announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125M, before deducting underwriting discounts and commissions and offering expenses payable by the company. The offering is expected to close on or about September 30, subject to the satisfaction of customary closing conditions. J.P. Morgan is acting as the sole book-running manager for the offering.
展开本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。